| Recurrence | Death without recurrence | Death after recurrence | ||||
---|---|---|---|---|---|---|---|
TR | 95% CI | TR | 95% CI | TR | 95% CI | ||
Age at Diagnosis (years) | Trend effect | 0.956 | 0.942–0.970 * | 0.996 | 0.906–1.135 | 0.999 | 0.961–1.037 |
Gender | Male | 0.835 | 0.624–0.972 * | 1.006 | 0.945–1.177 | 0.977 | 0.977–1.129 |
Metastasis to other sites | Yes | 1.063 | 1.063–1.086 * | 1.071 | 0.925–1.106 | 0.946 | 0.944–0.969* |
Number of chemotherapies | Trend effect | 1.069 | 0.989–1.069 | 1.019 | 0.909–1.147 | 1.045 | 1.045–1.045 |
Grade (differentiation level) | Well | Referent | --- | --- | --- | --- | --- |
Moderate | 0.974 | 0.877–1.062 | 1.059 | 0.950–1.078 | 0.996 | 0.947–1.001 | |
Poor | 0.944 | 0.721–0.961 * | 1.067 | 0.852–1.225 | 0.966 | 0.834–0.975* | |
Tumor size | Trend effect | 0.890 | 0.855–0.960 * | 1.002 | 0.972–1.038 | 1.039 | 1.000- 1.206* |
PT-Stage | T2 | Referent | --- | --- | --- | --- | --- |
T3 | 1.048 | 0.927–1.050 | 1.018 | 0.994–1.083 | 1.066 | 0.975–1.233 | |
T4 | 1.006 | 0.914–1.068 | 1.095 | 0.978–1.095 | 1.077 | 0.992–1.162 | |
TX | NC | NC | NC | NC | NC | NC | |
PN-Stage | N0 | Referent | --- | --- | --- | --- | --- |
N1 | 1.033 | 1.033–1.077* | 1.147 | 1.019–1.196 * | 1.057 | 1.019–1.057 | |
N2 | 1.048 | 0.939–1.252 | 1.075 | 1.009–1.251 * | 0.874 | 0.835–0.877 | |
NX | NC | NC | NC | NC | NC | NC |